DONOR LEUKOCYTE INFUSIONS AS TREATMENT OF EPSTEIN-BARR-VIRUS LYMPHOPROLIFERATIVE DISORDERS (EBV-LPD) IN RECIPIENTS OF UNRELATED AND RELATED ALLOGENEIC TRANSPLANTS

被引：0
|
作者：
PAPADOPOULOS, EB [1 ]
LADANYI, M [1 ]
机构：
[1] MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021
来源：
BLOOD | 1993年 / 82卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A214 / A214
页数：1
相关论文
共 50 条
  • [1] EPSTEIN-BARR-VIRUS (EBV)-INDUCED LYMPHOPROLIFERATIVE DISORDERS (LPD) MANIFESTING AS PLASMACYTOMAS
    MEDEIROS, LJ
    KINGMA, DW
    MARTIN, AW
    BARKER, RL
    JAFFE, ES
    PEIPER, SC
    LABORATORY INVESTIGATION, 1993, 68 (01) : A96 - A96
  • [2] KARYOTYPIC ABNORMALITIES IN EPSTEIN-BARR VIRUS ASSOCIATED LYMPHOPROLIFERATIVE DISEASE (EBV-LPD)
    HARRINGTON, D
    SPEAKS, S
    SANGER, W
    ARMITAGE, J
    PURTILO, D
    LABORATORY INVESTIGATION, 1989, 60 (01) : A39 - A39
  • [3] Unrelated donor leukocyte infusions (U-DLI) to treat relapse or EBV-lymphoproliferative disease (EBV-LPD) after unrelated donor bone marrow transplantation (BMT).
    Porter, D
    Collins, R
    Mick, R
    Kernan, N
    Giralt, S
    Flowers, M
    Casper, J
    Drobyski, W
    Leahey, A
    Parker, P
    Bates, B
    King, R
    Antin, J
    BLOOD, 1997, 90 (10) : 2622 - 2622
  • [4] PCR screening for Epstein-Barr virus-related Lymphoproliferative disease (EBV-LPD) among allogeneic stem cell transplant (AlloSCT) recipients: The importance of T cell depletion.
    Ambrossi, GG
    Jakubowski, A
    Brennan, C
    Kiehn, TF
    Weinstock, DM
    BLOOD, 2005, 106 (11) : 904A - 904A
  • [5] mTOR inhibitor monotherapy is insufficient to suppress viremia and disease progression in Epstein-Barr virus-driven lymphoproliferative disorders (EBV-LPD)
    Holtan, Shernan G.
    Porrata, Luis F.
    Colgan, Joseph P.
    Zent, Clive S.
    Habermann, Thomas M.
    Markovic, Svetomir N.
    AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (08) : 688 - 689
  • [6] Unsuccessful CTL transfusion in a case of post-BMT Epstein–Barr virus-associated lymphoproliferative disorder (EBV-LPD)
    S Imashuku
    T Goto
    T Matsumura
    M Naya
    M Yamori
    M Hojo
    S Hibi
    S Todo
    Bone Marrow Transplantation, 1997, 20 : 337 - 340
  • [7] Fatal outcome in a patient developing Epstein–Barr virus-associated lymphoproliferative disorder (EBV-LPD) without measurable disease
    M Ringhoffer
    K Döhner
    S Scheil
    H Wilts
    T Mertens
    W Grimminger
    H Döhner
    D Bunjes
    Bone Marrow Transplantation, 2001, 28 : 615 - 618
  • [8] Pre-emptive treatment with rituximab efficiently prevents EBV lymphoproliferative disease (EBV-LPD) in paediatric allogeneic stem cell recipients
    Kalpoe, J
    van Tol, M
    Bredius, R
    van Baarle, D
    Annels, N
    Claas, E
    Kroes, A
    Lankester, A
    BONE MARROW TRANSPLANTATION, 2004, 33 : S192 - S193
  • [9] ADOPTIVE IMMUNOTHERAPY WITH HUMAN EPSTEIN-BARR-VIRUS (EBV) SPECIFIC CYTOTOXIC T-LYMPHOCYTES (CTL) FOR THE TREATMENT OF SEVERE COMBINED IMMUNODEFICIENCY (SCID) MICE BEARING HUMAN EBV-INDUCED B-CELL LYMPHOPROLIFERATIVE DISORDERS (EBV-LPD)
    LACERDA, JF
    DENNIG, D
    LUCAS, K
    COLLINS, N
    LADANYI, M
    PAPADOPOULOS, E
    OREILLY, RJ
    BLOOD, 1994, 84 (10) : A398 - A398
  • [10] EPSTEIN-BARR virus associated lymphoproliferative disease (EBV-LPD) after T-cell depleted cell stem transplantation
    Liga, M.
    Carotti, A.
    Aloisi, T.
    Terenzi, A.
    Incamato, E.
    Sensini, A.
    De Carolis, L.
    D'Arro, B.
    Felicini, R.
    Gurdo, G.
    Martelli, M. F.
    Aversa, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 35 - 35
12345